Reuters logo
BRIEF-BioTime presents updated Opregen phase I/IIa trial data at AAO
November 15, 2017 / 1:22 PM / in a month

BRIEF-BioTime presents updated Opregen phase I/IIa trial data at AAO

Nov 15 (Reuters) - Biotime Inc:

* Presents updated Opregen phase I/IIa trial data at AAO

* There were no treatment-related serious adverse events after 15 months in trial​

* In addition to safety and tolerability, imaging suggests signs of engraftment and cell survival in trial​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below